Pharmaceutical Intermediates Market is Expected to Pegged around US$ 32,180 Mn by 2023, Due to Surge in Pharma Production Coupled with Increased Exports of API

“The Pharmaceutical Intermediates Market is anticipated to reach about US$ 32,180 Mn by 2023, and
anticipated to expand at a CAGR over six years of forecast period 2018-2023 owing to surge in the production
of pharmaceuticals coupled with the increased exports of APIs.

Precision Business Insights (PBI) in its report titled “Pharmaceutical Intermediates Market: Market
Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2023” assesses
the market performance over six years forecast period from 2018 to 2023. The report analyses the market
value forecast and provides the strategic insights into the market driving factors, challenges that are
hindering the market revenue growth over forecast period.

The Pharmaceutical Intermediates market size was accounted for US$ 26,457.0 Mn in 2018 and anticipated to
account for US$ 32,180.0 Mn by 2023. Increased prevalence of chronic diseases will create demand for novel
active pharmaceutical ingredients (API). Surge in the pharmaceutical production enables stimulate the demand
for pharmaceutical intermediates. Moreover, Escalated exports of APIs will also enhance the demand for
pharmaceutical intermediates.

Pharmaceutical Intermediates market segmented on the basis of application, end-user and country

A sample of this report is available upon request @ https://precisionbusinessinsights.com/market-reports/pharmaceutical-intermediates-market

Based on Application Type, The Pharmaceutical Intermediates market is segmented as anti-infective drugs,
cardiovascular drugs, central nervous system drugs, anti-diabetic drugs, anti-ulcerants, and others.
Cardiovascular drugs segment has been witnessed to account for major revenue share over the forecast period.
The API intermediates are raw materials which are responsible for therapeutic action. These can be converted
into the desired formulations such as capsules, tablets, and others.

Based on end-user type, pharmaceutical intermediates market segmented into pharmaceutical companies,
research laboratories, contract manufacturing organizations, and others. The pharmaceutical companies are
witnessed to account for major revenue share over the forecast period.

Precision Business Insights (PBI) Pharmaceutical Intermediates market report analyses the market in
different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According
to regional analysis, Asia Pacific accounted for major revenue share due to increased R&D investments in
China and India. Surge in the pharmaceutical production coupled with increased exports are witnessed to
offer lucrative opportunities for the market players plunged in the pharmaceutical intermediates market.

U.S. Pharmaceutical Intermediates market is accounted for major revenue share in North America, owing to
increased pharmaceutical production and robust investments in R&D.

The increased R&D investment from pharmaceutical companies, research organizations and biotech companies are
expected to create demand for pharmaceutical intermediates. Key player’s profiles in the report are Aceto
Corporation, BASF SE, Vertellus Holdings LLC, Lianhetech, Easter Chemical Corporation, Cycle Pharma Chem,
Dishman Group, Dextra Laboratories Limited, Chemcon Specialty Chemical Pvt. Ltd, Midas Pharma GmbH, Codexis,
A.R. Life Sciences Private Limited, Sanofi Winthrop Industries, and ZCL Chemical Ltd among others.

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Rest of Asia Pacific
• Latin America
  • China
  • Japan
  • India
  • ASEAN
  • Rest of Asia Pacific
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA

In January 2015, Johnson & Johnson partnered with Swiss biopharma AC Immune to develop a therapeutic
vaccine for the development of anti-tau Alzheimer’s vaccine.

Need more information about this report @ https://www.development.precisionbusinessinsights.com/market-reports/global-alzheimers-disease-treatment-market/

According to Centers for Disease Control and Prevention (CDC) the global prevalence of Alzheimer’s disease
will triple among elderly patients, and the prevalence increases to 13.8 million by 2050. Lost patents of
drug molecules and few more expected lose patents in near future, which is expected to create market
opportunity for generic players. Majority of drugs in pipeline failed in the late stage of clinical trials,
for instance, Eli Lilly’s Solanezumab and Pfizer/Johnson & Johnson’s Bapineuzumab have failed to prove
the disease-slowing effects in the late-stage of clinical trials.

Moreover, in 2014, FDA has approved cholinesterase inhibitors (Exelon, Aricept, and Razadyne) and memantine
for the treatment of cognitive symptoms in Alzheimer disease.

Researchers are considering new methods to treat Alzheimer’s disease to address the Alzheimer’s disease
market needs. The current drugs in the market help mask the symptoms but they do not stop the progression of
Alzheimer’s disease. There are several promising drugs in developmental and testing stage for Alzheimer’s
disease, but researchers need more funding of research to ensure that fresh ideas continue to fill the
pipeline.

Customisation of this report is available upon request @ https://www.development.precisionbusinessinsights.com/market-reports/global-alzheimers-disease-treatment-market/#ulp-c654SbFYO64MsOhu

Precision Business Insights is one of the leading market research and business consulting firm, which follow
a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to
achieve better results. We help our clients by providing actionable insights and strategies to make better
decisions. We provide consulting, syndicated and customised market research services based on our client
needs.

Contact us : Kemp House, 152 – 160 City Road, London EC1V 2NX

Email : sales@precisionbusinessinsights.com

Toll Free (US) : +1-866-598-1553